Skip to content

Staar Surgical

US · STAA #3168 by market cap
22.49 +0.13 +0.58%
Live - 5344 symbols - heartbeat 396s ago · 2026-10-08 09:58
Pre-market 22.00 -1.61%
After-hours 22.36 0.00%
Market cap
1.13B
P/B
3.09
EPS
-1.62
Reader sentiment Are you bullish or bearish on STAA?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 3.07 Cheap vs history 19th percentile
5-year average 6.90 · #30 of 51 in Medical Instruments & Supplies
P/E ratio 279.50 Expensive vs history 97th percentile
5-year average 74.50 · forward 45.13 · #26 of 27 in Medical Instruments & Supplies
P/S ratio 3.30 Cheap vs history 10th percentile
5-year average 8.19 · forward 3.19 · #32 of 51 in Medical Instruments & Supplies

Vs. peers Medical Instruments & Supplies

Company Market cap P/E (TTM) P/B Div yield
Staar Surgical (STAA) 1.13B 281.13 3.09 0.00%
Intuitive Surgical (ISRG) 145.26B 47.15 7.99 0.00%
Becton Dickinson & Co (BDX) 49.26B 54.63 2.02 2.32%
ResMed (RMD) 31.73B 21.63 4.82 1.06%
Medline (MDLN) 31.25B 67.58 2.70 0.00%
Alcon (ALC) 30.32B 47.89 1.40 0.56%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value27.83 Economic moatNone UncertaintyHigh

Trading 23.8% below Morningstar's fair value estimate.

Fair value

Staar Surgical Co receives a 4-star quantitative star rating, reflecting our opinion that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 20% discount to our quantitative fair value estimate of $27.83 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The company's profitability increases our estimated fair value. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. Reflecting the firm's profitability is its enterprise value to free cash flow ratio of 14.3, which ranks in the bottom 30% compared with global peers. This can be a sign of operational efficiency and potential for the company to fund growth, pay dividends, or reduce debt without needing additional capital. We believe this is a sign that shares could be undervalued.

On a different note, the firm's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to market value ratio of 0.9, for example, ranks in the bottom 30% compared with global peers. The market value of equity makes up a large fraction of enterprise value, indicating that shares have sharply risen, or that the company has a "lazy" balance sheet that is underleveraged. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has been a laggard relative to the broader universe over the past year. This underperformance makes the stock appear cheap, which portends a buying opportunity in light of other contributors to our model.

Economic moat

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-08 09:58:04 · For reference only, not investment advice and not tailored to your situation.